Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 6/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157201 | 0.80 | CYP1A2 (0.52) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL561882 | 0.80 | CYP1A2 (0.51) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL597180 | 0.78 | MEN1 (0.42) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL560905 | 0.77 | NOTUM (0.49) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL4157069 | 0.77 | CYP1A2 (0.48) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL4021797 | 0.77 | NOTUM (0.49) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL560874 | 0.76 | ELANE (0.57) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL15766372 | 0.76 | CTSK (0.46) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL15766614 | 0.76 | CTSK (0.41) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM | |
| SCHEMBL596606 | 0.76 | CYP1A2 (0.40) | CYP2C9NPSR1CYP1A2CYP2C19NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003858-A1 | MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS | SERPINB1, ELANE, MPO | CYP2C9 536/4885NPSR1 2947/4885CYP1A2 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.